NCT06854211Not yet recruitingPhase 1
Mechanisms of Opioid-induced Respiratory Depression (OIRD) During Sleep
Brigham and Women's Hospital1 site in 1 country26 target enrollmentStarted: July 1, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Brigham and Women's Hospital
- Enrollment
- 26
- Locations
- 1
- Primary Endpoint
- The change in ventilation (L) per minute during stable sleep with morphine versus placebo.
Study Overview
Brief Summary
The investigators are studying the impact that opioids have on breathing during sleep in healthy participants and those diagnosed with obstructive sleep apnea.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Healthy controls: Apnea Hypopnea Index (AHI) < 5 events/hr on in-laboratory PSG within 3 months of enrollment
- •OSA group: AHI > 10 events/hr on in-laboratory PSG within 3 months of enrollment; treated or untreated.
Exclusion Criteria
- •Sleep disordered breathing or respiratory disorders (other than OSA in the OSA group), such as central sleep apnea (>50% of respiratory events scored as central), chronic hypoventilation/hypoxemia (awake SaO2 < 92% by oximetry) due to chronic obstructive pulmonary disease or other respiratory conditions.
- •Other sleep disorders: periodic limb movements (periodic limb movement index > 20/hr), narcolepsy, or parasomnias.
- •Any unstable major medical condition.
- •Medications expected to stimulate or depress respiration (including other opioids taken at home, barbiturates, benzodiazepines, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
- •History of allergy to lidocaine or oxymetazoline.
- •Contraindications for morphine, including:
- •allergy to morphine or opioids
- •chronic obstructive pulmonary disease, asthma, or other significant respiratory disorders
- •kidney or liver dysfunction, as this can affect the metabolism and excretion of morphine, leading to increased risk of toxicity.
- •women who are pregnant or breastfeeding will be excluded due to potential risks to the fetus or infant.
- •history of substance abuse, particularly opioid abuse, will be excluded to prevent potential misuse or relapse.
- •current use of central nervous system depressants.
- •individuals with gastrointestinal obstruction. Constipation is not an exclusion criterion because morphine is only administered for one night.
- •recent head injury, brain tumors, or other conditions leading to increased intracranial pressure.
- •unstable heart disease, particularly those with risk factors for or a history of heart rhythm disorders.
- •epilepsy or a history of seizures, as morphine can lower the seizure threshold.
- •severe psychiatric conditions, particularly those with a history of psychosis, as opioids can exacerbate these conditions.
- •medications that interact with morphine, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), Monoamine oxidase inhibitors (MAOIs), and the atypical antidepressants buproprion and trazodone.
- •untreated or unstable endocrine disorders like adrenal insufficiency or thyroid dysfunction.
Arms & Interventions
Placebo
Placebo Comparator
Intervention: Placebo (Drug)
Morphine
Active Comparator
Intervention: Morphine p.o. (Drug)
Outcomes
Primary Outcomes
The change in ventilation (L) per minute during stable sleep with morphine versus placebo.
Time Frame: From enrollment to the end of treatment at 6 weeks.
The primary outcome, determining the change in ventilation in liters per minute, will be analyzed on both subpopulations (controls and people with obstructive sleep apnea) using generalized linear mixed models with treatment, period and sequence as fixed effects and a random effect of participant nested within sequence.
Secondary Outcomes
No secondary outcomes reported
Investigators
Danny J. Eckert
Principal Investigator
Brigham and Women's Hospital
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Impairment of Sleep and Pattern of Breathing Before and After Opioid Withdrawal in Comparison to Patients Without Opioid WithdrawalSleep Architecture Under Opioid MedicationNCT01540890Ruhr University of Bochum40
Completed
Not Applicable
PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY (PRODIGY)Patients monitored by capnoGraphYJPRN-UMIN000026993Covidien Japan Inc.1,650
Completed
Not Applicable
PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphYopoid induced RDrespiratory depression10038716NL-OMON42863Medtronic B.V.330
Withdrawn
Not Applicable
Incidence of Opioid-Induced Respiratory Depression in Medical and Trauma PatientsRespiratory DepressionSedationNCT03647696Poudre Valley Health System
Recruiting
Not Applicable
Study of sleep, respiratory control during sleep and quality of life in morbidly obese subjects undergoing bariatric surgery.We will study subjects with morbid obesity, considered nutritional and metabolic disease, undergone bariatric surgery, for investigation of sleep disorders, especially obstructive sleep apnea.E02.065.062C08.618.085.852.850C18.654.726.500C10.886RBR-9k9hhvniversidade Nove de Julho - UNINOVE